Literature DB >> 15544499

Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models.

Wan C Tsai1, Theodore J Standiford.   

Abstract

Macrolide antibiotics appear to play a role in the management of diseases of chronic airway inflammation, distinctly separate from their antibactericidal activity. In the last fifteen years, their success in human clinical trials has prompted both in-vitro and in-vivo investigations to determine the mechanisms by which this family of antibiotics modulate the immune response. A large body of evidence suggests that macrolides directly target multiple components of the inflammatory cascade that occur independent of bactericidal/bacteriostatic effects. We will review the existing data in support of immunomodulatory effects of macrolides on activated leukocytes at the site of lung inflammation, on pulmonary host cells, and in animal models of lung disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544499     DOI: 10.2174/1381612043383430

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  14 in total

1.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

2.  A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.

Authors:  Astrid Milić; Vlatka Bencetić Mihaljević; Jovica Ralić; Ana Bokulić; Danijela Nožinić; Branka Tavčar; Boris Mildner; Vesna Munić; Ivica Malnar; Jasna Padovan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-10       Impact factor: 2.441

Review 3.  Long-term macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Ganapathi Iyer Parameswaran; Sanjay Sethi
Journal:  CMAJ       Date:  2014-08-05       Impact factor: 8.262

4.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

Review 5.  Ureaplasma species: role in diseases of prematurity.

Authors:  Rose M Viscardi
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

6.  Effect of topical azithromycin on corneal innate immune responses.

Authors:  Zahra Sadrai; Amir Reza Hajrasouliha; Sunil Chauhan; Daniel R Saban; Mohammad H Dastjerdi; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-19       Impact factor: 4.799

7.  Exploring the role of the immune response in preventing antibiotic resistance.

Authors:  Andreas Handel; Elisa Margolis; Bruce R Levin
Journal:  J Theor Biol       Date:  2008-11-08       Impact factor: 2.691

8.  Non-peptide macrocyclic histone deacetylase inhibitors.

Authors:  Adegboyega K Oyelere; Po C Chen; William Guerrant; Sandra C Mwakwari; Rebecca Hood; Yunzhe Zhang; Yuhong Fan
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells.

Authors:  Xiugong Gao; Radharaman Ray; Yan Xiao; Peter E Barker; Prabhati Ray
Journal:  BMC Cell Biol       Date:  2007-05-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.